SE0402735D0 - Novel compounds - Google Patents
Novel compoundsInfo
- Publication number
- SE0402735D0 SE0402735D0 SE0402735A SE0402735A SE0402735D0 SE 0402735 D0 SE0402735 D0 SE 0402735D0 SE 0402735 A SE0402735 A SE 0402735A SE 0402735 A SE0402735 A SE 0402735A SE 0402735 D0 SE0402735 D0 SE 0402735D0
- Authority
- SE
- Sweden
- Prior art keywords
- novel compounds
- therapy
- processes
- pharmaceutically acceptable
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0402735A SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Novel compounds |
CA002585310A CA2585310A1 (en) | 2004-11-09 | 2005-11-07 | 5-heteroaryl thiazoles and their use as p13k inhibitors |
KR1020077012802A KR20070085837A (ko) | 2004-11-09 | 2005-11-07 | 5-헤테로아릴 티아졸 및 이것의 pi3k 억제제로서의 용도 |
AT05801592T ATE472546T1 (de) | 2004-11-09 | 2005-11-07 | 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren |
ES05801592T ES2346333T3 (es) | 2004-11-09 | 2005-11-07 | 5-heteroaril tiazoles y su uso como inhibidores de pi3k. |
AU2005303566A AU2005303566A1 (en) | 2004-11-09 | 2005-11-07 | 5-heteroaryl thiazoles and their use as P13K inhibitors |
DE602005022116T DE602005022116D1 (de) | 2004-11-09 | 2005-11-07 | 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren |
MX2007005546A MX2007005546A (es) | 2004-11-09 | 2005-11-07 | Tiazoles de 5-heteroarilo y su uso como inhibidores p13k. |
US11/667,064 US7868188B2 (en) | 2004-11-09 | 2005-11-07 | 5-heteroaryl thiazoles and their use as PI3K inhibitors |
EP05801592A EP1841763B1 (en) | 2004-11-09 | 2005-11-07 | 5-heteroaryl thiazoles and their use as pi3k inhibitors |
CNA2005800461365A CN101098869A (zh) | 2004-11-09 | 2005-11-07 | 5-杂芳基噻唑及其作为磷脂酰肌醇3-激酶抑制剂的用途 |
BRPI0517634-4A BRPI0517634A (pt) | 2004-11-09 | 2005-11-07 | derivado de tiazol ou um derivado farmaceuticamente aceitável do mesmo, processo para a preparação de um composto, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição |
JP2007539638A JP2008519021A (ja) | 2004-11-09 | 2005-11-07 | 5−ヘテロアリールチアゾール及びpi3k阻害剤としてのその使用 |
PCT/GB2005/004268 WO2006051270A1 (en) | 2004-11-09 | 2005-11-07 | 5-heteroaryl thiazoles and their use as p13k inhibitors |
UY29199A UY29199A1 (es) | 2004-11-09 | 2005-11-08 | Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones |
TW094139209A TW200621762A (en) | 2004-11-09 | 2005-11-09 | Novel compounds |
ARP050104699A AR052232A1 (es) | 2004-11-09 | 2005-11-09 | Derivados de 5-heteroariltiazoles |
IL182726A IL182726A0 (en) | 2004-11-09 | 2007-04-22 | 5-heteroaryl thiazoles and their use as p13k inhibitors |
NO20072259A NO20072259L (no) | 2004-11-09 | 2007-04-30 | Heteroaryltiazoler og deres anvendelse som P13K-inhibitorer |
ZA200703714A ZA200703714B (en) | 2004-11-09 | 2007-05-08 | 5-heteroaryl thiazoles and their use as P13K inhibitors |
HK08101781.3A HK1112895A1 (en) | 2004-11-09 | 2008-02-19 | 5-heteroaryl thiazoles and their use as pi3k inhibitors |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0402735A SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0402735D0 true SE0402735D0 (sv) | 2004-11-09 |
Family
ID=33488202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0402735A SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Novel compounds |
Country Status (21)
Country | Link |
---|---|
US (1) | US7868188B2 (sv) |
EP (1) | EP1841763B1 (sv) |
JP (1) | JP2008519021A (sv) |
KR (1) | KR20070085837A (sv) |
CN (1) | CN101098869A (sv) |
AR (1) | AR052232A1 (sv) |
AT (1) | ATE472546T1 (sv) |
AU (1) | AU2005303566A1 (sv) |
BR (1) | BRPI0517634A (sv) |
CA (1) | CA2585310A1 (sv) |
DE (1) | DE602005022116D1 (sv) |
ES (1) | ES2346333T3 (sv) |
HK (1) | HK1112895A1 (sv) |
IL (1) | IL182726A0 (sv) |
MX (1) | MX2007005546A (sv) |
NO (1) | NO20072259L (sv) |
SE (1) | SE0402735D0 (sv) |
TW (1) | TW200621762A (sv) |
UY (1) | UY29199A1 (sv) |
WO (1) | WO2006051270A1 (sv) |
ZA (1) | ZA200703714B (sv) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
MX2007014180A (es) * | 2005-05-10 | 2008-01-14 | Vertex Pharma | Derivados biciclicos como moduladores de canales de iones. |
BRPI0611176A2 (pt) | 2005-05-24 | 2010-08-17 | Serono Lab | derivados do tiazol e o uso dos mesmos |
CA2636077C (en) | 2006-01-18 | 2012-01-03 | Amgen Inc. | Thiazole compounds as protein kinase b (pkb) inhibitors |
EP1979346A1 (en) * | 2006-01-23 | 2008-10-15 | Laboratoires Serono S.A. | Thiazole derivatives and use thereof |
TW200806641A (en) | 2006-01-25 | 2008-02-01 | Synta Pharmaceuticals Corp | Substituted aromatic compounds for inflammation and immune-related uses |
CA2682189C (en) * | 2006-04-07 | 2015-12-08 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers |
EP2016075A1 (en) * | 2006-05-03 | 2009-01-21 | AstraZeneca AB | Thiazole derivatives and their use as anti-tumour agents |
DK1887359T3 (da) * | 2006-08-03 | 2009-03-02 | Cellzome Ag | Fremgangsmåde til identifikation af PI3K-interagerende molekyler og til rensning af PI3K |
WO2008027584A2 (en) * | 2006-09-01 | 2008-03-06 | Vertex Pharmaceuticals Incorporated | 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase |
GB0620059D0 (en) | 2006-10-10 | 2006-11-22 | Ucb Sa | Therapeutic agents |
GB0620818D0 (en) * | 2006-10-19 | 2006-11-29 | Ucb Sa | Therapeutic agents |
US8263585B2 (en) | 2007-05-04 | 2012-09-11 | Novartis Ag | Organic compounds |
AU2008276512A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of PKB |
EP2173728A2 (en) | 2007-07-17 | 2010-04-14 | Amgen Inc. | Heterocyclic modulators of pkb |
CN101765591B (zh) * | 2007-07-26 | 2013-11-27 | 诺华股份有限公司 | 用于治疗炎性或过敏性病症的嘧啶衍生物 |
CA2694136C (en) | 2007-08-02 | 2013-09-17 | Amgen Inc. | Pi3 kinase modulators and methods of use |
WO2009055418A1 (en) * | 2007-10-22 | 2009-04-30 | Smithkline Beecham Corporation | Pyridosulfonamide derivatives as pi3 kinase inhibitors |
JP5520831B2 (ja) | 2007-12-19 | 2014-06-11 | アムジエン・インコーポレーテツド | Pi3キナーゼの阻害薬 |
UY31545A1 (es) | 2007-12-20 | 2009-08-03 | Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones | |
JP2011514965A (ja) * | 2008-02-04 | 2011-05-12 | セルゾーム アーゲー | 複数の標的に対するpi3k相互作用分子の選択性プロファイリング |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
KR20100125426A (ko) * | 2008-03-19 | 2010-11-30 | 바이엘 크롭사이언스 아게 | 살진균제 히드록시모일-테트라졸 유도체 |
US20110160256A1 (en) * | 2008-06-26 | 2011-06-30 | Rouse Meagan B | Inhibitors of akt activity |
UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
WO2010079443A1 (en) | 2009-01-12 | 2010-07-15 | Pfizer Limited | Sulfonamide derivatives |
US20120039905A1 (en) * | 2009-01-13 | 2012-02-16 | The Babraham Institute | The Role of p110 delta Signaling in Morbidity and Lung Pathology Induced by Influenza Virus Infection |
US20110135655A1 (en) * | 2009-01-13 | 2011-06-09 | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication |
US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
ES2548571T3 (es) | 2009-04-02 | 2015-10-19 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | Derivados de imidazo[2,1-b][1,3,4]tiadiazol |
TW201103943A (en) * | 2009-04-27 | 2011-02-01 | Shionogi & Co | Urea derivative having pi3k inhibitory activity |
AU2010247414B2 (en) | 2009-05-15 | 2013-08-01 | Novartis Ag | Aryl pyridine as aldosterone synthase inhibitors |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
EP2448946B1 (en) | 2009-07-02 | 2013-07-24 | Novartis AG | 2-carboxamide cycloamino ureas useful as pi3k inhibitors |
WO2012006220A1 (en) * | 2010-07-07 | 2012-01-12 | Philadelphia Health & Education Corporation | Treatment of avian species with inhibitors of p110 delta signaling |
US9145407B2 (en) | 2010-07-09 | 2015-09-29 | Pfizer Limited | Sulfonamide compounds |
JP5648058B2 (ja) * | 2010-07-22 | 2015-01-07 | 扶桑薬品工業株式会社 | ベンゾフラノン化合物およびそれを含む医薬組成物 |
WO2012035171A2 (en) * | 2010-09-17 | 2012-03-22 | Kancera Ab | New compounds |
CN106518845B (zh) * | 2011-08-30 | 2019-09-13 | Chdi基金会股份有限公司 | 犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法 |
US9309236B2 (en) | 2011-10-05 | 2016-04-12 | The Board Of Trustees Of The Leland Stanford Junior University | PI-kinase inhibitors with broad spectrum anti-infective activity |
US9926309B2 (en) | 2011-10-05 | 2018-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with anti-infective activity |
EP2817292B1 (en) * | 2012-02-22 | 2019-12-18 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as tnap inhibitors |
JP6301316B2 (ja) | 2012-05-23 | 2018-03-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 内胚葉細胞および肝実質細胞の組成物ならびにそれらの細胞を入手および使用する方法 |
US20150258127A1 (en) * | 2012-10-31 | 2015-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
CN104797565A (zh) * | 2012-11-09 | 2015-07-22 | 法国国家健康医学研究院 | 新的苯磺酰胺噻唑化合物 |
US9745295B2 (en) | 2013-04-26 | 2017-08-29 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
WO2015095445A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
EP3082807B1 (en) | 2013-12-20 | 2018-07-04 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
WO2015095444A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
BR112016016289B1 (pt) | 2014-01-14 | 2023-02-07 | Takeda Pharmaceutical Company Limited | Heteroaris e usos dos mesmos |
WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
US9775839B2 (en) | 2014-03-13 | 2017-10-03 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
CN104016910A (zh) * | 2014-04-03 | 2014-09-03 | 定陶县友帮化工有限公司 | 一种2-氨基-3-氯-5-溴吡啶的合成方法 |
US10258621B2 (en) | 2014-07-17 | 2019-04-16 | Chdi Foundation, Inc. | Methods and compositions for treating HIV-related disorders |
CN104844589B (zh) * | 2014-12-26 | 2018-04-20 | 中国科学院合肥物质科学研究院 | 一种pi3k激酶抑制剂 |
EP3419980A4 (en) | 2016-02-26 | 2019-07-03 | The Board of Trustees of the Leland Stanford Junior University | INHIBITORS OF PI-KINASE WITH ANTI-INFECTIOUS ACTIVITY |
TW201811766A (zh) | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
EP3842439A4 (en) | 2018-08-21 | 2022-04-27 | Kyorin Pharmaceutical Co., Ltd. | BICYCLIC HETEROAROMATIC RING DERIVATIVE |
EP4085057A1 (en) | 2020-01-02 | 2022-11-09 | Helmholtz-Zentrum für Infektionsforschung GmbH | Novel pqsr inverse agonists |
CN116531373A (zh) * | 2022-01-26 | 2023-08-04 | 上海日馨医药科技股份有限公司 | 噻唑类化合物、其药物组合物及应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4649146A (en) * | 1983-01-31 | 1987-03-10 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives and pharmaceutical composition comprising the same |
GB8302591D0 (en) * | 1983-01-31 | 1983-03-02 | Fujisawa Pharmaceutical Co | Thiazole derivatives |
AUPP873799A0 (en) * | 1999-02-17 | 1999-03-11 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine compounds |
TWI314928B (en) * | 2002-02-28 | 2009-09-21 | Novartis A | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
GB0305152D0 (en) * | 2003-03-06 | 2003-04-09 | Novartis Ag | Organic compounds |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
-
2004
- 2004-11-09 SE SE0402735A patent/SE0402735D0/sv unknown
-
2005
- 2005-11-07 AT AT05801592T patent/ATE472546T1/de not_active IP Right Cessation
- 2005-11-07 KR KR1020077012802A patent/KR20070085837A/ko not_active Application Discontinuation
- 2005-11-07 CN CNA2005800461365A patent/CN101098869A/zh active Pending
- 2005-11-07 US US11/667,064 patent/US7868188B2/en not_active Expired - Fee Related
- 2005-11-07 CA CA002585310A patent/CA2585310A1/en not_active Abandoned
- 2005-11-07 MX MX2007005546A patent/MX2007005546A/es not_active Application Discontinuation
- 2005-11-07 EP EP05801592A patent/EP1841763B1/en active Active
- 2005-11-07 WO PCT/GB2005/004268 patent/WO2006051270A1/en active Application Filing
- 2005-11-07 BR BRPI0517634-4A patent/BRPI0517634A/pt not_active IP Right Cessation
- 2005-11-07 ES ES05801592T patent/ES2346333T3/es active Active
- 2005-11-07 AU AU2005303566A patent/AU2005303566A1/en not_active Abandoned
- 2005-11-07 JP JP2007539638A patent/JP2008519021A/ja active Pending
- 2005-11-07 DE DE602005022116T patent/DE602005022116D1/de active Active
- 2005-11-08 UY UY29199A patent/UY29199A1/es not_active Application Discontinuation
- 2005-11-09 TW TW094139209A patent/TW200621762A/zh unknown
- 2005-11-09 AR ARP050104699A patent/AR052232A1/es unknown
-
2007
- 2007-04-22 IL IL182726A patent/IL182726A0/en unknown
- 2007-04-30 NO NO20072259A patent/NO20072259L/no not_active Application Discontinuation
- 2007-05-08 ZA ZA200703714A patent/ZA200703714B/xx unknown
-
2008
- 2008-02-19 HK HK08101781.3A patent/HK1112895A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO20072259L (no) | 2007-06-06 |
BRPI0517634A (pt) | 2008-10-14 |
WO2006051270A1 (en) | 2006-05-18 |
US7868188B2 (en) | 2011-01-11 |
KR20070085837A (ko) | 2007-08-27 |
AU2005303566A1 (en) | 2006-05-18 |
AR052232A1 (es) | 2007-03-07 |
MX2007005546A (es) | 2007-06-19 |
ATE472546T1 (de) | 2010-07-15 |
ES2346333T3 (es) | 2010-10-14 |
TW200621762A (en) | 2006-07-01 |
ZA200703714B (en) | 2008-09-25 |
EP1841763A1 (en) | 2007-10-10 |
US20080132502A1 (en) | 2008-06-05 |
IL182726A0 (en) | 2007-07-24 |
JP2008519021A (ja) | 2008-06-05 |
CN101098869A (zh) | 2008-01-02 |
DE602005022116D1 (de) | 2010-08-12 |
CA2585310A1 (en) | 2006-05-18 |
EP1841763B1 (en) | 2010-06-30 |
HK1112895A1 (en) | 2008-09-19 |
UY29199A1 (es) | 2006-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0402735D0 (sv) | Novel compounds | |
EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
NO20071703L (no) | Kinazolinderivater | |
SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
EA201000092A1 (ru) | Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний | |
NO20090631L (no) | Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser | |
ATE514699T1 (de) | Substituierte pyrrolopyrazolderivate als kinaseinhibitoren | |
EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
EA201000090A1 (ru) | Тризамещенные производные пиримидина для лечения пролиферативных заболеваний | |
EA200802390A1 (ru) | Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их | |
TN2009000180A1 (en) | NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF | |
EA200701324A1 (ru) | Соединения пиридина для лечения заболеваний, опосредованных действием простагландина | |
ATE450533T1 (de) | Carboxamidderivate | |
MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
TW200700392A (en) | Novel compounds | |
EA200802007A1 (ru) | Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине | |
TW200639156A (en) | New compounds | |
DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
MX2007004248A (es) | Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa. | |
SE0401762D0 (sv) | Novel compounds | |
MX2007007027A (es) | Derivados piperazinilpiridina como agentes anti-obesidad. |